Company / EPS (Diluted)
Spero Therapeutics, Inc. EPS (Diluted) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.27
FY2025
5-year range
-$3.52 / $0.43
FY2021-FY2025
Trend
-395.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) changed -395% YoY in FY2025, a notable deviation from the 7-year average annual change of -17%.
Based on SEC 10-K filings.
-1.27 in FY2025.
Declined from $-1.23 to $-1.27 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 395.3% year-over-year.
- Peak eps (diluted) was recorded in FY2024.
- Lowest eps (diluted) in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.27 | -395.3% |
| FY2024 | $0.43 | +135.0% |
| FY2023 | -$1.23 | +57.7% |
| FY2022 | -$2.91 | +17.3% |
| FY2021 | -$3.52 | -5.1% |
| FY2020 | -$3.35 | -28.8% |
| FY2019 | -$2.60 | +97.3% |
| FY2018 | -$95.87 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026